Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects

NCT04591782 | Completed

• 1 other identifier: 18-001720
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Pomegranate fruits and products, including juice, tea, wine and extracts are widely consumed and recognized for their health benefits. Pomegranate fruit possesses strong antioxidant, anti-inflammatory and antiproliferative properties. The effects of pomegranate on type 2 diabetic (T2DM) conditions have previously been reported. Although 8 oz. of Pom juice (PJ) contains 36.9 g of sugar, 12-week PomJ supplementation did not change plasma advanced glycated end-products, fasting glucose and HbA1C, but reduced lipid peroxidation in T2D subjects. Additionally, acute PJ consumption has been shown to lower postprandial glycemic response of a meal with high glycemic index (GI) and lower fasting blood glucose, and long-term PomJ consumption did not worsen diabetic markers. However, a large knowledge gap still exists regarding the form of sugars in PJ and the hormonal responses to PJ consumption in different physiological conditions. Therefore currently the consumption of PJ is not recommended for individuals with T2DM. This clinical study will focus on the short-term effects of PJ consumption on different diabetic variables to further evaluate the health benefits of PJ for T2DM.

Conditions

Diabete Type 2; Pre Diabetes

Keywords

pomegranate; antioxidants; prediabetes

Outcome Measures

Primary Outcomes (4)

• Number of participants with acute response to sugar water vs. pom juice vs. water

  Compare the difference in blood glucose response to consuming PomJ compared to the same amount of sugar (fructose and glucose) mixed in water in a cross over study design

  2 hours

• Number of participants with hormonal changes in response to sugar water vs. pom juice vs. water

  Compare the plasma concentration of principle hormones involved in glucose regulation (insulin, C-peptide, glucagon) , gut hormones (GLP-1 and GIP) and triglycerides.

  15 days

• Number of participants with acute response of plasma nitric oxide (NO) from sugar water vs. pom juice vs. water

  Compare the acute response of plasma nitric oxide (NO) in participants who consume sugar alone, water alone or pomegranate juice

  2 hours

• Impact of gut microbiome in glycemic response to pom juice vs. sugar water

  Compare the glycemic response and the ability to form microbiote urolithin from pomegranate ellagatanins in participants who consume pom juice vs. water.

  15 days

Study Arms (3)

PomJuice (PJ)

EXPERIMENTAL

8 oz of PJ

Other: PomJuice

Sugar Water

ACTIVE COMPARATOR

8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it

Other: Sugar Water

Water

OTHER

8 oz of water

Other: Water

Interventions

PomJuice OTHER

Drink 8 oz pomegranate juice

PomJuice (PJ)

Water OTHER

Drink 8 oz water

Water

Sugar Water OTHER

Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in

Sugar Water

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 20-50 years and any racial/ethnic group
• Typically consume low fiber/polyphenol diet (beige diet)
• Healthy, normal weight individuals with a BMI of \>18 to 26.9 kg/ m2 with fasting serum glucose \<100mg/dL or A1c \<5.7
• Prediabetic, obese individuals with a BMI of \>27 kg/ m2 and fasting serum glucose \>100, but \<126 mg/dL or A1c \>5.7% but \< 6.4%\]
• Subjects must read and sign the informed consent prior to participation
• Subjects must be in generally good health
• Subjects must be able and willing to comply with the requirements of the protocol.

You may not qualify if:

• Eating a high fiber/polyphenol diet or taking any medication or dietary supplements that interfere with the absorption of polyphenols.
• History of gastrointestinal surgery, diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP \>160mmHg, diastolic BP \> 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history
• Any subject currently taking blood thinning medications such as Warfarin or Coumadin
• Currently uses tobacco products.
• Currently has an alcohol intake \> 20 g ⁄ day;
• Currently has a coffee intake \> 3 cups ⁄ day;
• Screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
• Using prebiotics, probiotics, yogurt, and/or any fiber supplements regularly
• Allergy or sensitivity to pomegranate. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded
• Taking antibiotics or laxatives within the past 3 months
• Is unable or unwilling to comply with the study protocol.

Sponsors & Collaborators

• University of California, Los Angeles: lead

Study Sites (1)

UCLA Center for Human Nutrition, 1000 Veteran Ave.

Los Angeles, California, 90095, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Glucose Intolerance; Prediabetic State

Interventions

Water

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Hyperglycemia

Intervention Hierarchy (Ancestors)

Hydroxides; Alkalies; Inorganic Chemicals; Anions; Ions; Electrolytes; Oxides; Oxygen Compounds

Study Officials

• Zhaoping Li, MD, PhD

  UCLA Professor of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief / Professor of Medicine

Study Record Dates

• First Submitted: October 2, 2020
• First Posted: October 19, 2020
• Study Start: February 1, 2019
• Primary Completion: December 20, 2021
• Study Completion: December 20, 2021
• Last Updated: May 6, 2023

Record last verified: 2023-05

Locations

US (1)